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Sustained intraocular VEGF 
neutralization results in retinal 
neurodegeneration in the Ins2Akita 
diabetic mouse
Jose R. Hombrebueno, Imran HA. Ali, Heping Xu & Mei Chen
Current therapies that target vascular endothelial growth factor (VEGF) have become a mainstream 
therapy for the management of diabetic macular oedema. The treatment involves monthly repeated 
intravitreal injections of VEGF inhibitors. VEGF is an important growth factor for many retinal cells, 
including different types of neurons. In this study, we investigated the adverse effect of multiple 
intravitreal anti-VEGF injections (200 ng/μl/eye anti-mouse VEGF164, once every 2 weeks totalling 
5–6 injections) to retinal neurons in Ins2Akita diabetic mice. Funduscopic examination revealed the 
development of cotton wool spot-like lesions in anti-VEGF treated Ins2Akita mice after 5 injections. 
Histological investigation showed focal swellings of retinal nerve fibres with neurofilament disruption. 
Furthermore, anti-VEGF-treated Ins2Akita mice exhibited impaired electroretinographic responses, 
characterized by reduced scotopic a- and b-wave and oscillatory potentials. Immunofluorescent 
staining revealed impairment of photoreceptors, disruptions of synaptic structures and loss of amacrine 
and retinal ganglion cells in anti-VEGF treated Ins2Akita mice. Anti-VEGF-treated WT mice also presented 
mild amacrine and ganglion cell death, but no overt abnormalities in photoreceptors and synaptic 
structures. At the vascular level, exacerbated albumin leakage was observed in anti-VEGF injected 
diabetic mice. Our results suggest that sustained intraocular VEGF neutralization induces retinal 
neurodegeneration and vascular damage in the diabetic eye.
Diabetic retinopathy (DR) affects almost 80% of individuals who have had diabetes for 1–2 decades1,2. Patients 
with DR may experience vision loss due to diabetic macular oedema (DMO) or proliferative DR (PDR) as a con-
sequence of progressive retinal vascular dysfunction. DMO occurs when fluid leaks from damaged blood vessels 
into the macula, compromising central vision. According to the Wisconsin Epidemiologic Study of Diabetic 
Retinopathy, around 20% of type-1 and 14 ~ 25% of type-2 diabetic patients have DMO1,3. PDR (characterized 
by retinal neovascularization), is present in around 20% of diabetic patients who have suffered from the disease 
for 30 years4. Retinal laser photocoagulation has been used to treat DMO and PDR5,6. In addition, DMO has also 
been treated with intravitreal steroid injections7. Over the last few years, the intravitreal injection of neutralizing 
antibodies against vascular endothelial growth factor (VEGF) has become a mainstream therapy for DMO. The 
therapy has shown promising results in stabilising DMO and reducing retinal thickness8–12 as well as in improving 
visual acuity in PDR13–15.
VEGF is known to play a crucial role in the pathogenesis of DMO by promoting blood-retinal barrier (BRB) 
disruption and exacerbated vascular leakage16,17. Since the intravitreal injection of anti-VEGF antibody does not 
tackle the upstream fundamental factors that cause DMO, symptoms may re-occur once intraocular drug levels 
decline. Therefore, repeated injections (every 4 ~ 6 weeks) are needed to maintain normal BRB function in diabetic 
eyes. VEGF plays an important role in the survival and function of retinal cells, including neurons18,19. VEGF is 
involved in a wide range of neuronal functions, including neurogenesis, neuronal survival and synaptogenesis 
(reviewed in19,20). Accordingly, the neutralization of VEGF in rodent models has been shown to be detrimental for 
retinal neurons. A previous study has shown that systemic neutralization of VEGF in mice resulted in substantial 
neural retinal cell death21. Also, genetic deletion of retinal pigment epithelium (RPE)-derived VEGF in adult mice 
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promoted rapid vision loss due to photoreceptor dysfunction22. Furthermore, chronic inhibition of VEGF in adult 
rats leads to retinal ganglion cell (RGCs) loss23.
Anti-VEGF therapy has been a mainstay treatment for patients with neovascular age-related macular degen-
eration (nAMD) for 8–10 years. Although the therapy reduces neovascular lesion and improves vision, there is a 
high incidence of retinal geographic atrophy characterised by RPE damage and photoreceptor cell death following 
the therapy24. These observations suggest that sustained VEGF depletion may pose severe adverse effects to the 
human retina. This is of particular concern to DR patients as 1) their retinas are more fragile than nAMD retina, 
and 2) they are generally a lot younger than nAMD patients and are expected to live for many more years and 
would thus require more anti-VEGF injections. It is therefore crucial to understand the long-term adverse effects 
of the therapy in patients with DR. In support of this concern, a recent study by Park et al.25 showed that intravitreal 
injection of a single dose of anti-VEGF resulted in increased inner retinal neuronal degeneration in diabetic rats. 
To elucidate this further, we investigated the long-term adverse effects of multiple intravitreal anti-VEGF injections 
in the Ins2Akita mouse, a model of type 1-diabetes26.
Results
Multiple intravitreal injections of anti-VEGF induced cotton wool spot like-lesions in the Ins2Akita 
mouse. No fundus abnormalities were observed in WT and Ins2Akita mice prior to intravitreal injections 
(Fig. 1a,d). Anti-VEGF treatment did not induce any retinal lesions in the WT mice (Fig. 1a–c). After 4 intravit-
real injections of anti-VEGF antibody, 60% of the eyes developed patches of brownish irregular shaped lesions in 
the Ins2Akita mouse (Fig. 1e). Following 5 injections, multiple whitish “cotton wool spot (CWS)”-like lesions were 
observed in 80% of the eyes in anti-VEGF treated Ins2Akita mice (Fig. 1f). These whitish lesions were observed 
at the superficial layer (i.e. nerve fibre layer (NFL)) of the retina and on top of retinal vessels, and were spread in 
all retinal sectors varying in size from ¼ to 2 optic disc (OD) diameters. No retinal damage was detected in IgG 
treated WT and Ins2Akita mice (Supplemental Fig. 1).
The thickness of the neuroretina was measured by Spectral Domain Optical Coherence Tomography 
(SD-OCT)  (Fig. 1g–l). Anti-VEGF injections significantly reduced the neuronal retinal thickness in both WT 
and Ins2Akita mice, although this reduction was more severe in Ins2Akita mice (p < 0.01; Fig. 1g–m). Interestingly, 
the OCT-reflectance of the inner plexiform layer (IPL) and NFL/ganglion cell layer (GCL) was weaker in the 
anti-VEGF treated eyes (Fig. 1i,l). Intravitreal injection of IgG did not affect retinal thickness in WT and Ins2Akita 
mice (Fig. 1m). Similar findings in fundus and SD-OCT images were observed when the experiment was repeated 
in a different set of mice.
Retinal histopathological changes following multiple anti-VEGF injections. Light microscopy 
analysis of hematoxylin and eosin (H&E) stained retinal sections showed no gross abnormalities in WT IgG, 
WT anti-VEGF or Ins2Akita IgG treated mice (Fig. 2a–c). In contrast, Ins2Akita mice injected with anti-VEGF 
exhibited focal lesions at the inner retinal layers, characterized by the swelling of the NFL/GCL and atypical cell 
infiltration (Fig. 2d, arrow). No morphological abnormalities were observed within the other layers of the retina. 
Immunostaining of retinal sections with NF-L showed normal distribution of RGC axons in IgG injected WT mice 
(Fig. 2e). Focal disruption or down-regulation of NF-L expression was observed in the retinas from anti-VEGF 
treated WT mice or IgG treated Ins2Akita mice (Fig. 2f,g). Severe disruption or a total loss of focal NF-L expression 
was observed in retinas from Ins2Akita mice following multiple anti-VEGF injections in focal areas corresponding 
to NFL/GCL swelling (Fig. 2h). Discrete mild NF-L disruptions, similar to that observed in Fig. 2f,g, were also 
detected in areas outside focal NFL/GCL swellings (data not shown). GFAP immunostaining revealed normal 
distribution of this intermediate filament in glial processes at the NFL/GCL and a faint thin expression at the IPL in 
IgG, anti-VEGF WT and IgG Ins2Akita treated mice (Fig. 2i–k). Extensive focal GFAP up-regulation was observed in 
anti-VEGF treated Ins2Akita mice (Fig. 2l). In addition, the accumulation of activated Iba-1+CD68+ microglial cells 
was observed at the NFL/GCL of anti-VEGF treated Ins2Akita mice (Fig. 2p), in the areas corresponding to NFL/GCL 
swelling and focal GFAP up-regulation. Taken together, our results suggest that sustained VEGF neutralization to 
the retina of Ins2Akita mice resulted in focal NFL damage, a classic pathological hallmark of CWS in human DR27,28.
Electoretinogram responses following intravitreal anti-VEGF injection. No significant differences 
in scotopic electroretinogram (ERG) parameters were observed between WT non-injected controls and WT IgG 
or WT anti-VEGF treated groups (Fig. 3a,c). A slight but statistically significant reduction of both a- and b-wave 
amplitudes at the higher light intensity was observed in IgG treated Ins2Akita mice (p < 0.05; Fig. 3b,d). Five intra-
vitreal injections of anti-VEGF in the Ins2Akita mouse resulted in a severe impairment of both a-wave and b-wave 
amplitudes and a significant reduction in the amplitudes of oscillatory potentials (OPs) compared to non-injected 
Ins2Akita controls (p < 0.05; Fig. 3b,d).
Retinal neuronal changes following multiple anti-VEGF intravitreal injections. Changes in photo-
receptor cells. Rod and cone photoreceptor cells were stained with antibodies against rhodopsin and cone-arrestin 
respectively (Fig. 4). Rhodopsin expression was confined to the outer segments of the rod photoreceptors in 
WT mice treated with IgG or anti-VEGF and in Ins2Akita mice treated with IgG (Fig. 4a–c). Ectopical expression 
of rhodopsin within the inner segments and somata of rod photoreceptors was observed in anti-VEGF treated 
Ins2Akita mice (Fig. 4d,e). No significant changes were observed in rod photoreceptor cell density within the dif-
ferent treatment groups (Fig. 4f).
Cone-arrestin staining showed that WT mice treated with IgG or anti-VEGF and Ins2Akita treated with IgG 
had normal cone photoreceptor cell morphology (Fig. 4g–i). However, a reduction in the length of the cone pho-
toreceptor segments and abnormal fragmentation were observed in anti-VEGF treated Ins2Akita mice (Fig. 4j–l). 
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Figure 1. Clinical examinations following intravitreal injections of anti-VEGF. Fundus images from WT 
(a–c) or Ins2Akita (d–f) mice at baseline (week 0) (a,d), 8 weeks (b,e) or 12 weeks (c,f) after intravitreal injections 
of anti-VEGF. Arrows indicate brownish irregular shaped lesions; Arrowheads indicate cotton wool spot-like 
lesions. SD-OCT representative images from WT (g–i) or Ins2Akita (j–l) mouse retinas of non-injected controls 
(g,j), intravitreal IgG (h,k) or anti-VEGF (i,l) treated mice at 12 weeks post-injection. (m) Quantitative 
analysis of neuroretinal thickness in WT and Ins2Akita non-injected, IgG or anti-VEGF treated mice (n = 6 
eyes per strain/condition). Results are presented as mean ± SEM. *P < 0.05, **P < 0.01 compared to non-
injected controls of the same strain. One-way ANOVA. NFL/GCL, nerve fibre/ganglion cell layer; IPL, inner 
plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; OLM, outer limiting membrane; IS/OS, 
photoreceptor inner/outer segments; RPE, retinal pigment epithelium.
www.nature.com/scientificreports/
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Furthermore, cone photoreceptor cell density was also significantly reduced compared to non-injected controls 
(p < 0.01; Fig. 4m).
The thickness of the ONL was also significantly reduced in Ins2Akita mice following anti-VEGF treatment. 
However, there was no reduction in ONL thickness in the IgG treated mice (Supplemental Fig. 2a,b).
Changes in outer plexiform layer and second order neurons. Presynaptic elements of rod and cone photoreceptor 
cells were investigated by using antibody against synaptophysin (Fig. 5). Synaptophysin was expressed predom-
inately at the outer plexiform layer (OPL), although faint expression was also detected at the outer nuclear layer 
(ONL). There was no significant alteration in the distribution and expression level of synaptophysin in WT mice 
treated with IgG or anti-VEGF and in Ins2Akita mice treated with IgG (Fig. 5a–h). In contrast, a significant increase 
in the expression of synaptophysin at the ONL was observed in anti-VEGF treated Ins2Akita mice (p < 0.05; Fig. 5i,j), 
suggesting a marked withdrawal of rod terminals from the OPL.
Synaptic elements of second order neurons were investigated by using antibodies against calbindin (horizontal 
cells), secretagogin (cone-bipolar cells) and PKCα (rod-bipolar cells). Neither intravitreal injections of IgG nor 
Figure 2. Histopathology of cotton wool spot (CWS)-like lesions after anti-VEGF treatment. Retinal 
sections from WT and Ins2Akita mice after 5 intravitreal injections of IgG or anti-VEGF were processed for 
H&E staining (a–d) or NF-L (e–h), GFAP (i–l) and Iba-1/CD68 (m–p) immunoreactivities. (d) CWS-lesion at 
the GCL/NFL (arrowheads) accompanied by atypical cell infiltration (arrow). (f,g) Slight disruption of NF-L+ 
axonal fibres (arrows) in anti-VEGF treated WT (f) or IgG treated Ins2Akita (g) mice. (h) Severe disruption of 
NF-L+ axonal fibres (arrowhead) in anti-VEGF treated Ins2Akita mice. (l,p) Focal up-regulation of GFAP and 
infiltration of Iba-1+CD68+ microglial cells in CWS-lesions. IPL, inner plexiform layer; GCL/NFL, ganglion 
cell/nerve fibre layer.
www.nature.com/scientificreports/
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anti-VEGF affected the number and distribution of horizontal cell dendritic boutons in WT mice (Fig. 6a–c). 
However, a significant reduction of dendritic boutons was observed in the Ins2Akita mouse following multiple 
anti-VEGF injections (p < 0.001; Fig. 6d–f). The density of horizontal-(data not shown), rod- and cone-bipolar 
cells (Supplemental Fig. 3) remained unchanged in WT and Ins2Akita mice in all treatment groups. In addition, no 
significant changes were observed in the density of synaptic processes at the IPL (from either rod- or cone-bipolar 
cells) (Supplemental Fig. 3).
The thickness of the OPL was significantly reduced in Ins2Akita mice following anti-VEGF treatment, in contrast 
to the IgG treated group, where the OPL thickness was unaffected (Supplemental Fig. 2c).
Changes in amacrine cells and retinal ganglion cells. GABAergic and glycinergic amacrine cells were evaluated 
using antibodies against GABA and GlyT1 respectively (Fig. 7). Compared to the non-injected controls, both WT 
and Ins2Akita mice treated with anti-VEGF presented a significant reduction of GABAergic and glycinergic amacrine 
cells (p < 0.05; Fig. 7a–f). The total number of amacrine cells (GABAergic + glycinergic) was significantly reduced 
in both WT and Ins2Akita mice following multiple anti-VEGF but not IgG injections (p < 0.01; Fig. 7g–i), although 
the level of reduction was more pronounced in Ins2Akita mice (Fig. 7i). This was reflected by a significant reduction 
of the overall thickness of INL and IPL in diabetic mice (Supplemental Fig. 2d,e).
Both WT and Ins2Akita mice presented a significant drop in Brn3a+ RGCs following anti-VEGF injections 
compared to the non-injected controls (p < 0.01; Fig. 8). The injection of isotype IgG did not affect RGCs density 
in both WT and Ins2Akita mice.
Retinal vascular changes following multiple anti-VEGF intravitreal injections. Collagen IV immu-
nostaining in WT mice showed normal distribution of the retinal vascular tree, characterised by three horizontal 
(ganglion cell layer (GCL), inner plexiform layer (IPL)/inner nuclear layer (INL) and OPL) and two interconnecting 
vertical plexuses (IPL and INL) (Fig. 9a–d). No changes were observed in the distribution and morphology of 
the different retinal vascular plexuses in WT and Ins2Akita mice in all treatment groups (Fig. 9a–d). In WT mice 
treated with IgG or anti-VEGF and in Ins2Akita mice treated with IgG, albumin immunostaining was mostly con-
fined within retinal vessels (Fig. 9e–g,i–k, arrowheads). However, diabetic mice treated with anti-VEGF showed 
marked extravascular staining of albumin throughout all retinal layers (Fig. 9h,l), suggesting abnormal leakage 
from retinal vessels.
Distribution of antibodies in mouse retina following intravitreal injection
To understand whether anti-VEGF antibody could diffuse into different retinal layers following intravitreal injec-
tion, fluorophore-conjugated anti-goat IgG was used to stain retinal sections from eyes receiving either anti-VEGF 
or IgG injections. Goat IgG immunoreactive puncta were detected in all retinal layers 24h following intravitreal 
injection of anti-VEGF or control IgG (Supplemental Fig. 4), suggesting that the antibodies were efficiently dis-
tributed through all retinal layers.
Figure 3. Abnormal electroretinogram (ERG) responses after anti-VEGF treatment. Scotopic ERG 
responses in WT and Ins2Akita mice after 5 intravitreal injections of IgG or anti-VEGF. (a,b) Representative 
scotopic ERG responses from WT (a) and Ins2Akita (b) mice of different treatment groups. (c,d) The amplitude 
(μ V) of a-wave, b-wave and oscillatory potentials in WT (c) and Ins2Akita (d) mice. (c,d) n = 5 mice per strain/
condition. Results are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to non-injected 
controls of the same strain. Two-way ANOVA.
www.nature.com/scientificreports/
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Figure 4. Photoreceptor abnormalities after anti-VEGF treatment. Retinal sections from WT and 
Ins2Akita mice after 5 intravitreal injections of IgG or anti-VEGF processed for rhodopsin or cone-arrestin 
immunostaining. (a–d) Confocal images of rhodopsin immunoreactivity of different treatment groups. (e,f) 
Mean luminance values of rhodopsin immunostaining at the ONL (box1) and rod photoreceptor cell density 
(difference between DAPI+ nuclei (box2) and cone somata (box3) at the ONL). (g–j) Confocal images of cone-
arrestin immunoreactivity of different treatment groups. (k-m) Quantitative analysis of cone segment length 
(box4) (k), cone segment disruption (cone-arrestin+ free particles above cone outer segments (box5)) (l) and 
cone photoreceptor density (m) in different treatment groups. n ≥ 20 retinal images per strain/condition. 
Results are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to non-injected controls 
of the same strain. One-way ANOVA. OS, outer segments; IS, inner segments; OLM, outer limiting membrane: 
ONL, outer nuclear layer; OPL, outer plexiform layer.
www.nature.com/scientificreports/
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Discussion
In this study, we showed that multiple intravitreal injections of anti-VEGF antibody resulted in significant neu-
roretinal degeneration and vascular leakage in Ins2Akita diabetic mice. Although most of the retinal neurons were 
affected, those within the inner retina, such as amacrine cells and RGCs presented more severe degeneration than 
neuronal cells close to the outer retina. Sustained VEGF neutralization also affected the neuroretina of WT mice, 
although the damage was restricted to the inner retina and to a lesser degree compared to diabetic mice.
Figure 5. Pre-synaptic changes at the OPL after anti-VEGF treatment. Retinal sections from WT and 
Ins2Akita mice after 5 intravitreal injections of IgG or anti-VEGF processed for synaptophysin immunoreactivity. 
(a–d) Confocal images of synaptophysin immunoreactivity from different treatment groups. (e) Quantitative 
analysis of synaptophysin+ area at the OPL (box1) and (f–j) ONL (thresholded white pixels enclosed in the 
yellow area (f)) in different treatment groups. n ≥ 20 retinal images per strain/condition. Results are presented 
as mean ± SEM. *P < 0.05 compared to non-injected controls of the same strain. One-way ANOVA. OLM, 
outer limiting membrane: ONL, outer nuclear layer; OPL, outer plexiform layer.
Figure 6. Horizontal cell dendritic boutons after anti-VEGF treatment. Retinal sections from WT (a–c) and 
Ins2Akita mice (d–f) after 5 intravitreal injections of IgG or anti-VEGF processed for calbindin immunoreactivity. 
(e) Loss of horizontal cell dendritic boutons (arrowheads) at the OPL in anti-VEGF treated Ins2Akita mice. The 
density of horizontal cell dendritic boutons (box1) in WT (c) and Ins2Akita (f) mice. n ≥ 20 retinal images per 
strain/condition. Results are presented as mean ± SEM. ***P < 0.001 compared to non-injected controls of the 
same strain. One-way ANOVA. OPL, outer plexiform layer; INL, inner nuclear layer.
www.nature.com/scientificreports/
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One of the most interesting observations of this study is the development of multiple CWS-like lesions in 
Ins2Akita mice following ≥ 5 intravitreal anti-VEGF injections. CWS is often observed in the fundus of patients with 
diabetes or hypertension28,29, but it has never been reported in rodent models. It is believed that they may evolve as 
boundary sentinels of inner retinal infarction resulting from focal ischemia27,28. Focal ischemia may cause axonal 
damage and consequently the obstruction of axoplasmic transport and accumulation of axoplasmic material within 
the NFL, promoting the focal swelling of the retinal surface and disruption of neurofilament27. We also observed 
focal disruptions of neurofilament and accumulation of Iba-1+CD68+ microglial cells in the anti-VEGF treated 
Ins2Akita mice. Infiltration of activated microglia has also been reported in human CWS30 as an adaptive immune 
response to axonal damage. The up-regulation of GFAP may reflect reactive gliosis from astrocytes and Müller 
cells due to neuronal damage31. The CWS was only observed in diabetic mice following 5 intravitreal anti-VEGF 
injections, suggesting the cumulative adverse effect of VEGF neutralization to inner retinal neurons. Whether NFL 
damage is caused by the direct effect of VEGF deprivation from neurons or secondary to vascular degeneration 
warrants further investigation.
Anti-VEGF mediated inner retinal damage was also characterized by the substantial reduction of amacrine cell 
and RGC densities. This was observed in both WT and Ins2Akita mice, although the latter exhibited more severe 
damage and dysfunctional changes (evidenced by abnormal OPs responses). Amacrine and RGC degeneration 
has been reported in STZ-induced diabetic rats following a single intravitreal injection of anti-VEGF25. RGC loss 
has also been reported in the healthy rat retina following intravitreal injection of Bevacizumab32 or after chronic 
inhibition of VEGF-A23, although this was not confirmed by others33,34. Our results suggest that sustained VEGF 
neutralization is detrimental to inner retinal neurons not only under diabetic conditions, but also in the healthy 
retina.
The neuronal structure of the outer retina in diabetic mice was also affected by sustained VEGF neutralization. 
This was evidenced by a significant reduction in cone photoreceptor cell density, disruption of cone photoreceptor 
Figure 7. Amacrine cell loss in WT and Ins2Akita anti-VEGF treated mice. Retinal sections from 
Ins2Akita mice after 5 intravitreal injections of IgG or anti-VEGF processed for GABA (a,b) and GlyT1 (d,e) 
immunoreactivities. (c,f,i) The density of GABAergic (box1), glycinergic (box2) and total amacrine cells 
(GABAergic + glycinergic) at the INL in different treatment groups. n ≥ 20 retinal images per strain/condition. 
Results are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to non-injected controls of 
the same strain. One-way ANOVA. INL, inner nuclear layer; IPL, inner nuclear layer.
www.nature.com/scientificreports/
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segments and redistribution of rhodopsin in rod cell somata (all well-known signs of photoreceptor cell stress35–37), 
and synaptic impairment at the OPL. The cellular changes in photoreceptor cells were in concordance with the 
abnormal scotopic a-wave response observed in the ERG analysis. VEGF is an important survival factor for photo-
receptors and systemic neutralization of VEGF results in photoreceptor cell apoptosis21. In addition, VEGF-receptor 
2, known to mediate pro-survival signals in neuronal cells19,23 is strongly expressed in photoreceptor cells21. VEGF is 
also critically involved in synaptic plasticity and function19,38. Cone photoreceptor cell loss and synaptic impairment 
of the OPL features retinal neurodegeneration in rodent models of DR39,40, including the Ins2Akita mouse41. Our 
results suggest that sustained VEGF neutralization may accelerate outer retinal degeneration in diabetic Ins2Akita 
eyes. This may be of significant relevance, as human DR also presents outer retinal deficits42,43. In addition to the 
direct effect of VEGF depletion on neurons, other factors, in particular anti-VEGF associated vascular damage 
may also contribute to retinal neuronal degeneration (see below) as chronic VEGF antagonism is known to affect 
the integrity of the choriocapillaris22.
Although both inner and outer retinal neurons were affected by intravitreal anti-VEGF injections, the damage 
in the inner retina was more severe than that observed in the outer retina. The antibody can efficiently diffuse to 
all retinal layers within 24h after injection, suggesting that the increased damage in the inner retina (i.e., RGCs 
and amacrine cells) is not caused by unequal distribution of the antibody, rather, it may suggest that inner retinal 
neurons are more sensitive to VEGF depletion. At least two factors may contribute to this phenomenon. Firstly, 
inner retinal neurons may be more susceptible to hyperglycaemia than outer retinal neurons and therefore more 
fragile to changes in the availability of neurotrophic factors. In this regard, ganglion cell and amacrine cell degen-
eration has been frequently observed in diabetic experimental models41,44. Secondly, the inner BRB damage caused 
by VEGF depletion may result in vascular dysfunction-dependent neurodegeneration.
VEGF is an important growth factor for post-mitotic neurons in the central nervous system19,23 and vascular 
endothelial cells45. Under diabetic conditions, retinal neurons, endothelial cells and pericytes undergo progressive 
degeneration46 as a result of sustained hyperglycaemia. We found that repeated injection of anti-VEGF induced 
marked albumin leakage in the retina of diabetic mice - a sign of BRB disruption. Although retinal leukostasis and 
acellular capillary has been described in the Ins2Akita mice, the mice do not develop severe DR related vasculop-
athy by 5 months of age47,48. Furthermore, the Ins2Akita mice do not secrete abnormal levels of VEGF at this stage 
of DR47. Therefore, the lack of pathogenic retinal VEGF levels and/or severe VEGF-associated vasculopathy in 
Ins2Akita mice may result in anti-VEGF antibody binding to “innocent” targets, including vascular cells and neurons, 
leading to further neuronal and vascular damage. The leakage of albumin and other plasma proteins into retinal 
parenchyma will inevitably induce inflammation, which may also contribute to retinal neuronal degeneration in 
anti-VEGF treated Ins2Akita mice.
A number of factors may limit the translation of our results to clinical practice in DMO patients. Firstly, the 
diabetic mice only develop mild vascular degeneration, and may not have pathological VEGF in the retina. In this 
regard, the anti-VEGF treatment thought to neutralize retinal pathogenic levels of VEGF in diabetic patients may 
deplete physiological VEGF in diabetic mice. Secondly, the differences in the affinity of the anti-mouse VEGF 
antibody used in this study compared to those specific clinical formulations (e.g. Bevacizumab or Ranibizumab) 
make it difficult to predict to what level the VEGF neutralization is harmful to the diabetic retina. Moreover, other 
Figure 8. Retinal ganglion cell loss in WT and Ins2Akita anti-VEGF treated mice. Retinal sections from 
WT (a–c) and Ins2Akita mice (d–f) after 5 intravitreal injections of IgG or anti-VEGF processed for Brn3a 
immunoreactivity. (c,f) The density of Brn3a+ cells in different treatment groups. n ≥ 20 retinal images per 
strain/condition. Results are presented as mean ± SEM. **P < 0.01 compared to non-injected controls of the 
same strain. One-way ANOVA. IPL, inner nuclear layer; NFL/GCL, nerve fibre/ganglion cell layer.
www.nature.com/scientificreports/
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experimental factors such as cross-species reactivity (e.g. goat IgG to mice) and inflammatory reaction to buffers 
used in antibody stabilization may contribute to the retinal phenotype observed in anti-VEGF treated mice. 
Nevertheless, our results show that sustained neutralization of VEGF in a pre-clinical model of type-1 diabetes 
promoted retinal neurodegeneration and induced vascular leakage. Although the proven benefit of anti-VEGF 
therapy in most DMO patients, a significant number of patients do not respond to the therapy49,50, suggesting 
that other factors may be fundamental in the pathogenesis of DMO in those non-responders. If this is indeed the 
case, our results suggest that the anti-VEGF therapy may potentially carry an “off-target” risk and the therapy may 
need to be applied more judiciously to avoid non-desirable side-effects. Even for the responders, the frequency of 
anti-VEGF needs to be carefully controlled to avoid potential depletion of physiological VEGF. Further clinical 
studies on how anti-VEGF therapy may impact on retinal physiological VEGF levels, will help to understand 
whether the therapy carries any long-term risk to DMO patients.
Methods
Animals. Male heterozygous Ins2Akita mice (3 months of age) of C57BL/6J background (Cat 003548 - originally 
purchased from Jackson Laboratory, Bar Harbor, USA) and age-matched non-diabetic siblings were used. The 
Ins2Akita mice develop robust hyperglycemia by 4.5 weeks of age26. Ins2Akita heterozygous males were bred with 
female C57BL/6J mice and diabetes confirmed by blood glucose test (> 250 mg/dl) in 6 weeks old littermates. All 
mice were housed in a pathogen-free animal housing room on a 12/12-hour light/dark cycle with free access to 
food and water. All procedures were conducted under the regulation of the UK Home Office Animals (Scientific 
Procedures) Act 1986 and approved by the Ethical Review Committee of Queen’s University Belfast. The study was 
Figure 9. Retinal vascular changes in WT and Ins2Akita anti-VEGF treated mice. Retinal photomicrographs 
of collagen-IV (red) and albumin (green) immunoreactivities in WT (a,b,e,f,i-i) and Ins2Akita (c,d,g,h,k,l) after 
5 intravitreal injections of IgG or anti-VEGF. (i–k) Albumin confined within retinal vessels (arrowheads). ONL, 
outer nuclear layer; INL, inner nuclear layer; IPL, inner nuclear layer; GCL/NFL, ganglion cell layer/nerve fibre 
layer.
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conducted in compliance with the Association for Research in Vision & Ophthalmology Statement for the Use of 
Animals in Ophthalmology and Vision Research.
Intravitreal injection. Intravitreal injections were performed as previously described51. 1 μ l of goat 
anti-mouseVEGF164 (200 ng/μ l; endotoxin-free, AF-493-NA; R&D Systems, Abingdon, UK) or endotoxin-free 
goat IgG (200 ng/μ l; AB-108C; R&D Systems) in 0.01 M phosphate buffered saline (PBS, pH 7.4) was injected in 
3-month old Ins2Akita or C57BL/6J siblings using a repeating dispenser (PB-600-1; Hamilton Bonaduz AG, Bonaduz, 
Switzerland). The AF-493-NA antibody has been shown to efficiently neutralize the bio-activity of mouse VEGF164 
in vivo52. The dose for intravitreal injection was chosen from a previous study by Nishijima et al.23. The injections 
were performed in the right eye with a 2-week time interval. The experiment was conducted twice. The total number 
of injections was 6 in study 1 (n = 6 mice per group) and 5 in study 2 (n = 6 mice per group). Age-matched mice 
that did not receive any intravitreal injections served as full controls in each study.
Clinical investigations. Animals were anesthetized by isoflurane inhalation and pupils dilated using 1% tropi-
camide and 2.5% phenylephrine (Chauvin, Essex, UK). A topic endoscopic fundus imaging system was used as pre-
viously described53,54, to obtain fundus images at baseline level (prior the first injection) and 2 weeks following each 
intravitreal injection. For SD-OCT examination, animals were anesthetized with ketamine hydrochloride (60 mg/
kg; Fort George Animal Centre, Southampton, UK) and xylazine (5 mg/kg; Pharmacia & Veterinary Products, 
Kiel, Germany) and pupils dilated. The examination was conducted 2 weeks after the final intravitreal injection 
(n = 5 ~ 6 animals per group) using the Spectralis Heidelberg OCT system (Heidelberg Engineering, Heidelberg, 
Germany), set to a 30° field of view. The thickness of the neuroretina (from the NFL to the apical border of the 
RPE) was measured at ~600 μ m distance from the optic disc (OD) in dorsal-ventral and nasal-temporal sectors 
by two independent researchers. Retinal thickness was then averaged in each mouse for further statistical analysis.
Electroretinography. Scotopic ERGs responses were evaluated 2 weeks following the final intravitreal injec-
tion (n ≥ 5 animals per group) as previously described41. Briefly, dark-adapted mice were deeply anesthetized 
with ketamine hydrochloride and xylazine and pupils dilated. ERGs were recorded using mouse corneal ERG 
electrodes in response to single white light flash, delivered by a standard Ganzfeld Stimulator (LKC Technologies, 
Gaithersburg, MD, USA). The amplitude of the scotopic a-wave, b-wave and OPs (summed amplitude of wavelets 
2–5) was measured.
Immunohistochemistry. Two weeks following the final intravitreal injection with anti-VEGF or IgG, mice 
were sacrificed by CO2 inhalation and eyes dissected and fixed in 2% paraformaldehyde for 2h. Eyes were then 
processed for immunohistochemistry as previously described55 and examined by confocal microscopy (C1-Nikon 
Confocal Microscope, Eclipse TE200-U, Nikon UK Ltd, Surrey, UK). A list with the primary antibodies used in the 
study is shown in Supplemental Table 1. Some of the retinal sections were processed for standard H&E staining 
and examined by light microscopy (Nikon Eclipse E400- Nikon UK Ltd). The diffusion efficiency of anti-VEGF 
and control IgG antibodies was tested as previously reported by Michael et al.56 In brief, retinal cryosections from 
WT mice were stained with Alexa fluor-488 donkey anti-goat IgG for 2 h in room temperature (1:200) 24 hours 
after intravitreal injection with goat IgG or anti-VEGF.
Retinal morphometry. Confocal images were used to quantify retinal neurons and synaptic structures (n = 3 
animals per group). Data was obtained from 3 sections per eye at center-middle retinal eccentricities (0.6 and 1.5 
from the OD). During image acquisition, confocal settings remained constant and images were then analyzed using 
FIJI software (National Institutes of Health, Bethesda, MD). The following parameters were analyzed: 1) rod and 
cone photoreceptor cell density (rods calculated as difference between the number of cone somata and DAPI+ 
nuclei at the ONL), 2) cone segment length (outer segment plus inner segment), 3) cone segment fragmentation 
(cone-arrestin+ free particles at the photoreceptor segment layer), 4) intensity of rhodopsin immunostaining at the 
ONL, 5) Area of synaptophysin-immunoreactive puncta at the OPL and ONL, 6) horizontal cell dendritic spine 
density, 7) horizontal cell, rod-bipolar and cone-bipolar cell density, 8) rod- and cone-bipolar cell axon bouton 
density, 9) GABAergic and glycinergic amacrine cell density, and 10) RGCs density. The thickness of each retinal 
layer (ONL, OPL, INL, IPL and GCL/NFL) was measured in cryosections stained for GABA, GlyT1 and DAPI by 
two independent researchers (Supplemental Fig. 2).
At least 20 retinal images per strain/age were analyzed and values averaged and normalized to 100 μ m retinal 
length. The intensity of rhodopsin immunostaining was measured from confocal images captured under constant 
photomultiplier settings, in which the mean luminance values (average brightness per pixel) were calculated from 
manually traced areas across the ONL (from the OPL to the outer limiting membrane). Luminance values were 
estimated from an average selection of at least 1000 pixels to ensure a high degree of variance. Background images 
were acquired from a vacant area of the labeled section and subtracted from the raw images to eliminate back-
ground noise. To quantify the density of synaptophysin-immunoreactive puncta, the ONL was manually traced 
and inverted. Mean luminance values of synaptophysin immunostaining at the OPL were then used to define 
minimum threshold values and the resulting images analyzed via the FIJI analyze particles tool. The density of 
synaptophysin-immunoreactive puncta was normalized to the ONL area.
Data analysis. SD-OCT retinal thickness and morphometric data in each strain of mice were analyzed using 
one-way ANOVA, followed by post-hoc Bonferroni’s pairwise comparisons. ERG responses (scotopic a-wave, 
b-wave and OPs) were analyzed using 2-way ANOVA followed by post-hoc Bonferroni’s pairwise comparisons. 
Data were expressed as mean ± SEM and p < 0.05 was considered statistically significant.
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